[go: up one dir, main page]

ECSP10010589A - Farmaco contra el cancer de higado - Google Patents

Farmaco contra el cancer de higado

Info

Publication number
ECSP10010589A
ECSP10010589A EC2010010589A ECSP10010589A ECSP10010589A EC SP10010589 A ECSP10010589 A EC SP10010589A EC 2010010589 A EC2010010589 A EC 2010010589A EC SP10010589 A ECSP10010589 A EC SP10010589A EC SP10010589 A ECSP10010589 A EC SP10010589A
Authority
EC
Ecuador
Prior art keywords
chemotherapeutic agent
liver cancer
antiglipican
antibody
pharmaceutical composition
Prior art date
Application number
EC2010010589A
Other languages
English (en)
Inventor
Masamichi Sugimoto
Takahiro Ishiguro
Yasuko Kinoshita
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41135076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010589(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/JP2008/002690 external-priority patent/WO2009041062A1/ja
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of ECSP10010589A publication Critical patent/ECSP10010589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan una composicion farmaceutica novedosa para tratar o prevenir carcinoma hepatocelular y un metodo de tratamiento. Se obtiene una composicion farmaceutica para tratar o prevenir cancer de higado al combinar un agente quimioterapeutico con un anticuerpo 3 antiglipicano. Tambien se describe una composicion farmaceutica para tratar o prevenir cancer de higado que comprende como un ingrediente activo un anticuerpo 3 antiglipicano para uso en combinacion con un agente quimioterapeutico, o que comprende como un ingrediente activo un agente quimioterapeutico para uso en combinacion con un anticuerpo 3 antiglipicano. La utilizacion del agente quimioterapeutico y el anticuerpo 3 antiglipicano en combinacion proporciona mejores efectos terapeuticos que utilizando solo el agente quimioterapeutico, y mitiga los efectos colaterales que surgen del tratamiento contra el cancer de higado tratamiento con el agente quimioterapeutico.
EC2010010589A 2008-04-04 2010-11-04 Farmaco contra el cancer de higado ECSP10010589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008098309 2008-04-04
PCT/JP2008/002690 WO2009041062A1 (ja) 2007-09-28 2008-09-26 血漿中動態が改善されたグリピカン３抗体

Publications (1)

Publication Number Publication Date
ECSP10010589A true ECSP10010589A (es) 2010-12-30

Family

ID=41135076

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010589A ECSP10010589A (es) 2008-04-04 2010-11-04 Farmaco contra el cancer de higado

Country Status (23)

Country Link
US (1) US20110104157A1 (es)
EP (1) EP2275135A4 (es)
JP (2) JP5306327B2 (es)
KR (1) KR101612139B1 (es)
CN (1) CN102046200B (es)
AR (1) AR071003A1 (es)
AU (1) AU2009233301B2 (es)
BR (1) BRPI0911147A2 (es)
CA (1) CA2720359A1 (es)
CL (1) CL2009000647A1 (es)
CO (1) CO6300964A2 (es)
CR (1) CR11769A (es)
EC (1) ECSP10010589A (es)
IL (1) IL208451A0 (es)
MA (1) MA32360B1 (es)
MX (1) MX2010010954A (es)
NZ (1) NZ588913A (es)
PE (1) PE20091655A1 (es)
RU (1) RU2523897C2 (es)
SG (1) SG189754A1 (es)
TW (1) TWI468175B (es)
UA (1) UA103614C2 (es)
WO (1) WO2009122667A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1674111E (pt) * 2004-07-09 2010-12-15 Chugai Pharmaceutical Co Ltd Anticorpo anti-glipicano 3
WO2006046751A1 (ja) * 2004-10-26 2006-05-04 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗グリピカン３抗体
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
CA2700986A1 (en) * 2007-09-28 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
CN104520331B (zh) 2012-06-01 2018-09-07 美国政府(由卫生和人类服务部的部长所代表) 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
EP3557260B1 (en) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
KR102409014B1 (ko) 2014-05-08 2022-06-14 추가이 세이야쿠 가부시키가이샤 Gpc3 표적 치료제 요법이 유효한 환자에게 투여되는 gpc3 표적 치료제
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
RU2683020C2 (ru) * 2014-11-11 2019-03-26 Петр Иванович Никитин Субстанция и способ для модуляции активности агента в организме
IL300476B2 (en) * 2015-06-30 2024-07-01 Eiger Group Int Inc Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
WO2017002934A1 (ja) 2015-07-01 2017-01-05 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
IL257324B (en) * 2015-08-03 2022-08-01 Carsgen Therapeutics Ltd Antibody against glypican-3 and its use
TW202248213A (zh) * 2016-03-15 2022-12-16 日商中外製藥股份有限公司 使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
US20230071098A1 (en) * 2018-07-17 2023-03-09 Noile-Immune Biotech, Inc. Anti-gpc3 single-chain antibody-containing car
KR102154683B1 (ko) * 2019-11-08 2020-09-11 주식회사 압타머사이언스 글리피칸-3 특이적 변형 압타머 및 이의 용도
KR20220155588A (ko) * 2020-03-18 2022-11-23 주식회사 유틸렉스 Gpc3 car-t 세포 조성물 및 이의 제조 및 사용 방법
CN115461449A (zh) * 2020-03-18 2022-12-09 优特力克斯有限公司 分泌il-18的gpc3 car-t细胞及其制备和使用方法
CN117062834A (zh) * 2021-02-10 2023-11-14 先声再明医药有限公司 Gpc3人源化抗体及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS6459878A (en) 1987-08-31 1989-03-07 Matsushita Electric Industrial Co Ltd Semiconductor laser protective circuit
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
GB9425138D0 (en) * 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
PL218428B1 (pl) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
US20040236080A1 (en) 2001-06-22 2004-11-25 Hiroyuki Aburatani Cell proliferation inhibitors containing anti-glypican 3 antibody
WO2003028696A2 (en) * 2001-10-03 2003-04-10 Celator Technologies Inc. Compositions for delivery of drug combinations
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
JP2006523457A (ja) * 2003-04-02 2006-10-19 セレーター ファーマスーティカルズ、インク． コンビネーション治療の個別化方法
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
DE102004032634A1 (de) * 2004-07-06 2006-02-16 Sms Demag Ag Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
PT1674111E (pt) * 2004-07-09 2010-12-15 Chugai Pharmaceutical Co Ltd Anticorpo anti-glipicano 3
JP4331227B2 (ja) * 2004-07-09 2009-09-16 中外製薬株式会社 抗グリピカン３抗体
DK1800693T3 (da) * 2004-08-24 2013-10-21 Chugai Pharmaceutical Co Ltd Adjuvans-terapi ved anvendelse af anti-glypican 3 antistoffer
WO2006046751A1 (ja) * 2004-10-26 2006-05-04 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗グリピカン３抗体
EP2208783A1 (en) * 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
EP1921078B1 (en) * 2005-08-05 2013-01-09 Chugai Seiyaku Kabushiki Kaisha Multikinase inhibitor
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007053573A2 (en) * 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
US20070185069A1 (en) * 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
EP1982718A4 (en) * 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
WO2007099988A1 (ja) * 2006-02-28 2007-09-07 Kyowa Hakko Kogyo Co., Ltd. α-1,6-フコシルトランスフェラーゼ変異体とその用途
WO2007114319A1 (ja) * 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
US9670269B2 (en) * 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
WO2007137170A2 (en) * 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
JP4640675B2 (ja) 2006-06-20 2011-03-02 清水建設株式会社 空調システム
JP4463793B2 (ja) 2006-10-10 2010-05-19 浜松ホトニクス株式会社 光検出装置
AU2008275985B2 (en) * 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
EP3127921A1 (en) * 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
CA2700986A1 (en) * 2007-09-28 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma

Also Published As

Publication number Publication date
TWI468175B (zh) 2015-01-11
CO6300964A2 (es) 2011-07-21
CA2720359A1 (en) 2009-10-08
IL208451A0 (en) 2010-12-30
CN102046200B (zh) 2015-03-25
KR20100132060A (ko) 2010-12-16
HK1151734A1 (en) 2012-02-10
AU2009233301A1 (en) 2009-10-08
TW200950804A (en) 2009-12-16
NZ588913A (en) 2012-10-26
PE20091655A1 (es) 2009-11-04
BRPI0911147A2 (pt) 2019-09-24
MA32360B1 (fr) 2011-06-01
JP5306327B2 (ja) 2013-10-02
KR101612139B1 (ko) 2016-04-12
CR11769A (es) 2011-03-30
MX2010010954A (es) 2011-03-24
US20110104157A1 (en) 2011-05-05
CL2009000647A1 (es) 2010-06-04
UA103614C2 (uk) 2013-11-11
RU2523897C2 (ru) 2014-07-27
RU2010145177A (ru) 2012-05-20
EP2275135A4 (en) 2013-03-06
CN102046200A (zh) 2011-05-04
JPWO2009122667A1 (ja) 2011-07-28
WO2009122667A1 (ja) 2009-10-08
EP2275135A1 (en) 2011-01-19
SG189754A1 (en) 2013-05-31
JP5506654B2 (ja) 2014-05-28
JP2011068682A (ja) 2011-04-07
AU2009233301B2 (en) 2014-01-23
AR071003A1 (es) 2010-05-19

Similar Documents

Publication Publication Date Title
ECSP10010589A (es) Farmaco contra el cancer de higado
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
UY31724A (es) " compuestos heterocíclicos novedosos y usos de los mismos"
NI201200179A (es) Métodos de tratamiento contra el cáncer pancreático
MX346861B (es) Metodos de tratamiento de carcinoma hepato celular.
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
NI200700064A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos.
MX2016013027A (es) Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario.
PH12012502399A1 (en) Combination therapy methods for treating proliferative diseases
PE20121709A1 (es) Una composicion farmaceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CL2011002648A1 (es) Composicion topica que comprende un compuesto derivado de 1,2,4-tiadiazol o tiourea, un agente modificador de la viscosidad, un conservante y agua; estuche para la composicion; metodo para preparar la composicion; y uso para tratar una enfermedad o trastorno dermatologico mediado por un receptor de melanocortina tal como acne.
PE20170470A1 (es) Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdidad de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes
WO2014160216A3 (en) Dual targeting anticancer agents
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
CL2008002758A1 (es) Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento.
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
MX391965B (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
NI201200196A (es) Agentes terapéuticos 976